Filtered By:
Specialty: Neurology
Management: Food and Drug Administration (FDA)

This page shows you your search results in order of date.

Order by Relevance | Date

Total 26 results found since Jan 2013.

Recycled Translation: Repurposing Drugs for Stroke
AbstractStroke, which continues to be a leading cause of death and long-term disability worldwide, has often been described as a clinical graveyard. While multiple small molecule therapeutics have undergone clinical trials in stroke, currently only one Food and Drug Administration (FDA)-approved medication exists for the treatment of stroke, the biological, recombinant tissue plasminogen activator (rt-PA). Repurposing of therapeutics which have previously gained FDA approval for alternative indications serves as a prospective option for stroke therapeutic translation. In contrast to de novo drug development, repurposing st...
Source: Translational Stroke Research - February 26, 2022 Category: Neurology Source Type: research

Sustainability of Intravenous Alteplase Administration via Telephone-Based Consult: Data from a US Health System
Despite multiple advances in management over the last few decades, acute ischemic stroke (AIS) is still associated with high morbidity and mortality.1 Intravenous alteplase (IV tPA) was shown to be efficacious and safe for AIS about a quarter century ago2 and remains the only Food and Drug Administration-approved medication for this indication. Though ideal, stroke neurologists may not be available in-person to decide whether to administer tPA to an AIS patient.
Source: Journal of Stroke and Cerebrovascular Diseases - January 27, 2022 Category: Neurology Authors: Sarah E. Nelson, Eric Aldrich, Brenda Johnson, Susan Groman, Richard E. Thompson, Victor Urrutia Source Type: research

FDA OKs First Vagus Nerve Stimulation System for Stroke Rehab FDA OKs First Vagus Nerve Stimulation System for Stroke Rehab
The US Food and Drug Administration has approved a first-of-its kind vagus nerve stimulation system to treat moderate-to-severe upper extremity motor deficits associated with chronic ischemic stroke.FDA Approvals
Source: Medscape Neurology and Neurosurgery Headlines - August 27, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

The emerging role of FTY720 as a sphingosine 1 ‐phosphate analog for the treatment of ischemic stroke: The cellular and molecular mechanisms
Three important mechanisms for neuroprotective effects of FTY720 have been described. Functional antagonistic, functional agonistic and receptor-independent mechanisms. Here, we review these mechanisms in more details and describe animal model and in clinical trial studies AbstractFinding novel and effective drugs for the treatment of ischemic stroke is warranted because there is not a definitive treatment for this prevalent disease. Due to the relevance between the sphingosine 1-phosphate (S1P) receptor and several neurological diseases including ischemic stroke, it seems that fingolimod (FTY720), as an agonist of S1P rec...
Source: Brain and Behavior - May 10, 2021 Category: Neurology Authors: Maryam Naseh, Jafar Vatanparast, Ali Rafati, Mahnaz Bayat, Masoud Haghani Tags: REVIEW Source Type: research

Tenecteplase for Acute Ischemic Stroke Treatment
Semin Neurol DOI: 10.1055/s-0040-1722722The introduction of thrombolytic therapy in the 1990s has transformed acute ischemic stroke treatment. Thus far, intravenous recombinant tissue plasminogen activator (rt-PA) also known as alteplase is the only thrombolytic proven to be efficacious and approved by the United States Food and Drug Administration. But the thrombolytic agent tenecteplase (TNK) is emerging as a potential replacement for rt-PA. TNK has greater fibrin specificity, slower clearance, and higher resistance to plasminogen activator inhibitor-1 than rt-PA. Hence, TNK has the potential to provide superior lysis wi...
Source: Seminars in Neurology - January 20, 2021 Category: Neurology Authors: Baird, Alison E. Jackson, Richard Jin, Weijun Tags: Review Article Source Type: research

Psychostimulant use disorder emphasizing methamphetamine and the opioid -dopamine connection: Digging out of a hypodopaminergic ditch
Approved food and drug administration (FDA) medications to treat Psychostimulant Use Disorder (PUD) are needed. Both acute and chronic neurological deficits related to the neurophysiological effects of these powerfully addictive drugs can cause stroke and alterations in mood and cognition.
Source: Journal of the Neurological Sciences - November 27, 2020 Category: Neurology Authors: Kenneth Blum, Jean Lud Cadet, Mark S. Gold Tags: Review Article Source Type: research

Medication Adherence and Stroke Prevention: What Real World Data Tells Us.
Authors: Hsieh CY Abstract Medication adherence, by definition,(2) is "the extent to which a patient acts in accordance with the prescribed interval and dose of a dosing regimen." Poor medication adherence can interfere with the ability to treat many diseases, leading to greater complications and a lower quality of life.(3) In this issue of Acta Neurologica Taiwanica, Chen et al.(4) presented the inverse association between adherence of antithrombotic agents and poor outcomes after a first-ever ischemic stroke. The findings were consistent with Sung, et al.(5) that medication nonadherence are prevalent in young adu...
Source: Acta Neurologica Taiwanica - February 7, 2020 Category: Neurology Tags: Acta Neurol Taiwan Source Type: research

Folic Acid Exerts Post-Ischemic Neuroprotection In Vitro Through HIF-1 α Stabilization
AbstractThe constant failure of single-target drug therapies for ischemic stroke necessitates the development of novel pleiotropic pharmacological treatment approaches, to effectively combat the aftermath of this devastating disorder. The major objective of our study involves a multi-target drug repurposing strategy to stabilize hypoxia-inducible factor-1 α (HIF-1α) via a structure-based screening approach to simultaneously inhibit its regulatory proteins, PHD2, FIH, and pVHL. Out of 1424 Food and Drug Administration (FDA)-approved drugs that were screened, folic acid (FA) emerged as the top hit and its binding potential...
Source: Molecular Neurobiology - October 5, 2018 Category: Neurology Source Type: research

Evaluating the Effect of Six Proton Pump Inhibitors on the Antiplatelet Effects of Clopidogrel
The objective of the present study was to examine the robustness of this interaction using a well-controlled study design in a population of participants free of confounders.
Source: Journal of Stroke and Cerebrovascular Diseases - February 12, 2018 Category: Neurology Authors: Eugene R. Przespolewski, Erica S. Westphal, Michelle Rainka, Nicholas M. Smith, Vernice Bates, Fran M. Gengo Source Type: research

Re-evaluate the Efficacy and Safety of Human Urinary Kallidinogenase (RESK): Protocol for an Open-Label, Single-Arm, Multicenter Phase IV Trial for the Treatment of Acute Ischemic Stroke in Chinese Patients
AbstractAcute ischemic stroke (AIS) is a major medical challenge in China. Thrombolytic drugs recommended for the treatment of AIS usually have a narrow time window. Human urinary kallidinogenase (HUK) was approved by the China Food and Drug Administration (CFDA) in 2005 for the treatment of mild to moderate AIS, and it is thus widely used in China. However, large-scale clinical study data for a more complete understanding of various aspects of its safety and efficacy characteristics are still unavailable. The ongoing Reevaluate the Efficacy and Safety of Human Urinary Kallidinogenase (RESK) trial is designed to reevaluate...
Source: Translational Stroke Research - March 5, 2017 Category: Neurology Source Type: research

IV tPA for acute ischemic stroke: Times are changing
Based on evidence that the administration of IV tissue plasminogen activator (tPA) improved the outcomes of selected patients with acute ischemic stroke, the US Food and Drug Administration (FDA) approved its use for this purpose in 1996, leading to a revolution in stroke care.1 Following its introduction into routine clinical practice, stroke began to be viewed as a medical emergency, similar to myocardial infarction, with effective treatment dependent or early symptom recognition and patient transport to facilities capable of conducting rapid evaluations and IV tPA administration. There were, however, considerable barrie...
Source: Neurology - November 20, 2016 Category: Neurology Authors: Goldstein, L. B. Tags: Medical care, All Cerebrovascular disease/Stroke, All epidemiology EDITORIALS Source Type: research

A call for formal telemedicine training during stroke fellowship
During the 20 years since US Food and Drug Administration approval of IV tissue plasminogen activator for acute ischemic stroke, vascular neurology consultation via telemedicine has contributed to an increased frequency of IV tissue plasminogen activator administration and broadened geographic access to the drug. Nevertheless, a growing demand for acute stroke coverage persists, with the greatest disparity found in rural communities underserved by neurologists. To provide efficient and consistent acute care, formal training in telemedicine during neurovascular fellowship is warranted. Herein, we describe our experiences in...
Source: Neurology - May 8, 2016 Category: Neurology Authors: Jagolino, A. L., Jia, J., Gildersleeve, K., Ankrom, C., Cai, C., Rahbar, M., Savitz, S. I., Wu, T.-C. Tags: All Health Services Research, All Cerebrovascular disease/Stroke, All Education CONTEMPORARY ISSUES: INNOVATIONS IN EDUCATION Source Type: research

The role of Akt (protein kinase B) and protein kinase C in ischemia-reperfusion injury.
Authors: Zhao EY, Efendizade A, Cai L, Ding Y Abstract Stroke is a leading cause of long-term disability and death in the United States. Currently, tissue plasminogen activator (tPA), is the only Food and Drug Administration-approved treatment for acute ischemic stroke. However, the use of tPA is restricted to a small subset of acute stroke patients due to its limited 3-h therapeutic time window. Given the limited therapeutic options at present and the multi-factorial progression of ischemic stroke, emphasis has been placed on the discovery and use of combination therapies aimed at various molecular targets contrib...
Source: Neurological Research - April 21, 2016 Category: Neurology Tags: Neurol Res Source Type: research